Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled ""Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%"".